Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
Kumler I, Knoop AS, Jessing CAR, et al. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open. 2016;1(4):e000062.
American Cancer Society. Breast cancer facts and figures 2015–2016. 2015. https://www.cancer.org. Accessed 17 Nov 2017.
Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(1):16–33.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Breast cancer version 3.2017. 2017. http://www.nccn.org. Accessed 11 Dec 2017.
AstraZeneca UK Limited. Faslodex 250 mg solution for injection: EU summary of product characteristics. 2017. http://www.ema.europa.eu/ema. Accessed 11 Dec 2017.
AstraZeneca. Faslodex® (fulvestrant) injection, for intramuscular use: US prescribing information. 2017. https://www.accessdata.fda.gov. Accessed 11 Dec 2017.
Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs. 2011;71(3):363–80.
Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–73.
Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739–46.
Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.
Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2–6.
de Cupis A, Noonan D, Pirani P, et al. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharmacol. 1995;116(5):2391–400.
Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994;54(6):1587–95.
DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer. 1994;70(2):204–11.
Coradini D, Biffi A, Cappelletti V, et al. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res. 1994;14(3A):1059–64.
Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer. 1993;55(5):873–6.
Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87(10):746–50.
Bundred NJ, Anderson E, Nicholson RI, et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 2002;22(4):2317–9.
DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994;54(2):408–14.
Howell A, DeFriend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 1996;74(2):300–8.
Frassoldati A, Guarneri V, Conte P. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. Cancer Biol Ther. 2009;8(15):1456–8.
Belagali YR, Barkate HV, Sejpal JJ, et al. Therapeutic place of fulvestrant in the management of hormone-receptor positive breast cancer. Eur Oncol Haematol. 2016;12(1):44–50.
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.
Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5.
Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136(2):503–11.
Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781–7.
Robertson JFR, Cheung K-L, Noguchi S, et al. Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON) [abstract no. 1048]. J Clin Oncol. 2017;35(15 Suppl.).
Roberston JFR, Di Leo A, Fazal M, et al. Fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral vs non-visceral metastases: findings from FALCON, FIRST, and CONFIRM [abstract]. In: San Antonio Breast Cancer Symposium, 2017.
Nunes AP, Green E, Dalvi T, et al. A real-world evidence study to define the prevalence of endocrine therapy-naive hormone receptor-positive locally advanced or metastatic breast cancer in the US [abstract no. P5-08-20]. Cancer Res. 2017;77(4 Suppl.).
Bastiaannet E, Charman J, Borge Johannesen T, et al. A real-world evidence study of patients with hormone receptor positive locally advanced or metastatic breast cancer at primary diagnosis [abstract no. 377]. Eur J Cancer. 2016;57(Suppl. 2):S107–8.
Boer K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2017;9(7):465–79.
Ding H, Fang L, Xin W, et al. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. Eur J Cancer Care (Engl). 2017. https://doi.org/10.1111/ecc.12733.
Robert NJ, Denduluri N. Patient case lessons: endocrine management of advanced breast cancer. Clin Breast Cancer. 2017. https://doi.org/10.1016/j.clbc.2017.05.014.
Telford C, Takyar S, Joshi P, et al. A network meta-analysis of fulvestrant vs alternative first-line endocrine therapies for endocrine therapy-naive postmenopausal hormone receptor-positive advanced or metastatic breast cancer [abstract no. e12545]. J Clin Oncol. 2017;35(15 Suppl).
Zhang J, Huang Y, Wang C, et al. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: a network meta-analysis. Medicine (Baltimore). 2017;96(33):e7846.
Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev. 2017;59:22–32.
Baatjes KJ, Apffelstaedt JP, Kotze MJ, et al. Postmenopausal breast cancer, aromatase inhibitors, and bone health: what the surgeon should know. World J Surg. 2016;40(9):2149–56.
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.